South and Central America Cardiometabolic Diseases Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Type (Cardiovascular disease (CVD), Type 2 diabetes, Hypertension, and Obesity), Treatment (ACE Inhibitors, Diuretics, Glucophage, and Others), Dosage (Tablet, and Injection), Route of Administration (Oral, and Intravenous), End Users (Hospital, Clinic, and Homecare Settings), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

No. of Pages: 157
Report Code: TIPRE00026140
Category: Life Sciences
South and Central America Cardiometabolic Diseases Market

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Data Triangulation and Validation

4. South and Central America Cardiometabolic Diseases Market Landscape

4.1 Overview
4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. South and Central America Cardiometabolic Diseases Market – Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints

6. South and Central America Cardiometabolic Diseases Market Regional Analysis

6.2 South and Central America Cardiometabolic Diseases Market Revenue 2019-2028 (US$ Million)
6.3 South and Central America Cardiometabolic Diseases Market Forecast Analysis

7. South and Central America Cardiometabolic Diseases Market Analysis – by Type

7.1 Cardiovascular disease
  • 7.1.1 Overview
  • 7.1.2 Cardiovascular disease: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Type 2 diabetes
  • 7.2.1 Overview
  • 7.2.2 Type 2 diabetes: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Hypertension
  • 7.3.1 Overview
  • 7.3.2 Hypertension: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.4 Obesity
  • 7.4.1 Overview
  • 7.4.2 Obesity: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)

8. South and Central America Cardiometabolic Diseases Market Analysis – by Treatment

8.1 ACE Inhibitors
  • 8.1.1 Overview
  • 8.1.2 ACE Inhibitors: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Diuretics
  • 8.2.1 Overview
  • 8.2.2 Diuretics: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.3 Glucophage
  • 8.3.1 Overview
  • 8.3.2 Glucophage: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)

9. South and Central America Cardiometabolic Diseases Market Analysis – by Dosage

9.1 Tablet
  • 9.1.1 Overview
  • 9.1.2 Tablet: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Injection
  • 9.2.1 Overview
  • 9.2.2 Injection: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)

10. South and Central America Cardiometabolic Diseases Market Analysis – by Route of Administration

10.1 Oral
  • 10.1.1 Overview
  • 10.1.2 Oral: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.2 Intravenous
  • 10.2.1 Overview
  • 10.2.2 Intravenous: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast, 2019-2028 (US$ Million)

11. South and Central America Cardiometabolic Diseases Market – South and Central America Analysis

11.1 Overview

11.2 South and Central America
  • 11.2.1 South and Central America Cardiometabolic Diseases Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 11.2.1.1 South and Central America Cardiometabolic Diseases Market – Revenue and Forecast Analysis – by Country
  • 11.2.1.1 Brazil: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.1.1 Brazil: South and Central America Cardiometabolic Diseases Market Breakdown, by Type
    • 11.2.1.1.2 Brazil: South and Central America Cardiometabolic Diseases Market Breakdown, by Treatment
    • 11.2.1.1.3 Brazil: South and Central America Cardiometabolic Diseases Market Breakdown, by Dosage
    • 11.2.1.1.4 Brazil: South and Central America Cardiometabolic Diseases Market Breakdown, by Route of Administration
  • 11.2.1.2 Argentina: South and Central America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.2.1 Argentina: South and Central America Cardiometabolic Diseases Market Breakdown, by Type
    • 11.2.1.2.2 Argentina: South and Central America Cardiometabolic Diseases Market Breakdown, by Treatment
    • 11.2.1.2.3 Argentina: South and Central America Cardiometabolic Diseases Market Breakdown, by Dosage
    • 11.2.1.2.4 Argentina: South and Central America Cardiometabolic Diseases Market Breakdown, by Route of Administration
  • 11.2.1.3 Rest of South and Central America : South and Central America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.3.1 Rest of South and Central America : South and Central America Cardiometabolic Diseases Market Breakdown, by Type
    • 11.2.1.3.2 Rest of South and Central America : South and Central America Cardiometabolic Diseases Market Breakdown, by Treatment
    • 11.2.1.3.3 Rest of South and Central America : South and Central America Cardiometabolic Diseases Market Breakdown, by Dosage
    • 11.2.1.3.4 Rest of South and Central America : South and Central America Cardiometabolic Diseases Market Breakdown, by Route of Administration

12. Competitive Landscape

12.1 Heat Map Analysis
12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments

14. Company Profiles

14.1 Bayer AG
  • 14.1.1 Key Facts
  • 14.1.2 Business Description
  • 14.1.3 Products and Services
  • 14.1.4 Financial Overview
  • 14.1.5 SWOT Analysis
  • 14.1.6 Key Developments
14.2 Novartis AG
  • 14.2.1 Key Facts
  • 14.2.2 Business Description
  • 14.2.3 Products and Services
  • 14.2.4 Financial Overview
  • 14.2.5 SWOT Analysis
  • 14.2.6 Key Developments
14.3 Boehringer Ingelheim International Gmbh
  • 14.3.1 Key Facts
  • 14.3.2 Business Description
  • 14.3.3 Products and Services
  • 14.3.4 Financial Overview
  • 14.3.5 SWOT Analysis
  • 14.3.6 Key Developments
14.4 Novo Nordisk A/S
  • 14.4.1 Key Facts
  • 14.4.2 Business Description
  • 14.4.3 Products and Services
  • 14.4.4 Financial Overview
  • 14.4.5 SWOT Analysis
  • 14.4.6 Key Developments
14.5 AstraZeneca
  • 14.5.1 Key Facts
  • 14.5.2 Business Description
  • 14.5.3 Products and Services
  • 14.5.4 Financial Overview
  • 14.5.5 SWOT Analysis
  • 14.5.6 Key Developments
14.6 Kowa Company, Ltd.
  • 14.6.1 Key Facts
  • 14.6.2 Business Description
  • 14.6.3 Products and Services
  • 14.6.4 Financial Overview
  • 14.6.5 SWOT Analysis
  • 14.6.6 Key Developments

15. Appendix

15.1 About Business Market Insights
15.2 List of Abbreviations

The List of Companies - South and Central America Cardiometabolic Diseases Market

  • Bayer AG
  • Novartis AG
  • Boehringer Ingelheim International Gmbh
  • Novo Nordisk A/S
  • AstraZeneca
  • Kowa Company, Ltd.
  • Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)